LOS ANGELES CAPITAL MANAGEMENT LLC
Position in MYGN — Myriad Genetics Inc
CIK 1177206
LOS ANGELES, CA
Position in MYGN
as of Jun 30, 2026
· filed Aug 13, 2026
Position Value
$396,930
+$4,620 QoQ
Shares Held
69,515
-20.3% QoQ
Ownership
0.073%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#79
of 196 holders
Holding Since
Sep 2025
4 quarters on record
Voting authority
Sole 26%
Shared 0%
None 74%
Common Shares in MYGN Over Time
Shares Held
Position Value (USD)
Position in Diagnostics & Research
Healthcare · as of Jun 30, 2026LOS ANGELES CAPITAL MANAGEMENT LLC holds $124,148,206 across 27 Diagnostics & Research names. MYGN ranks #10 (0.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | A |
Agilent Technologies, Inc.
|
477,841 | $63,471,620 | |
| 2 | IQV |
Iqvia Holdings Inc.
|
131,127 | $25,336,358 | |
| 3 | NTRA |
Natera, Inc.
|
48,046 | $13,042,086 | |
| 4 | IDXX |
Idexx Laboratories Inc /De
|
17,602 | $9,266,396 | |
| 5 | MEDP |
Medpace Holdings, Inc.
|
10,200 | $5,401,818 | |
| 6 | VCYT |
Veracyte, Inc.
|
69,585 | $4,086,727 | |
| 7 | TMO |
Thermo Fisher Scientific Inc.
|
1,631 | $817,718 | |
| 8 | GH |
Guardant Health, Inc.
|
3,578 | $536,807 |
All Filings in MYGN
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $396,930 | 69,515 | Shares | Sole | 2026-08-13 | |
| 2026-03-31 | $392,310 | 87,180 | Shares | Sole | 2026-05-08 | |
| 2025-12-31 | $599,126 | 97,419 | Shares | Sole | 2026-02-11 | |
| 2025-09-30 | $588,493 | 81,396 | Shares | Sole | 2025-10-20 | |
| No filing history on record for this holder in this stock. | ||||||